Key result
One-step high-dose isoproterenol tilt testing safely reproduces neurocardiogenic syncope in ~43% of previously negative patients.
Why the study?
Is a one-step high-dose isoproterenol tilt table test protocol safe, tolerable, and effective for diagnosing suspected neurocardiogenic syncope?
Observational (n=300)
Is a one-step high-dose isoproterenol tilt table test protocol safe, tolerable, and effective for diagnosing suspected neurocardiogenic syncope?
A one-step high-dose isoproterenol tilt table test protocol is safe, well-tolerated, and expeditious for diagnosing neurocardiogenic syncope in patients who test negative on unmedicated tilt.
Answers are grounded in this paper and cite their sources.
May support expanded diagnostic testing in tilt-negative syncope; leaves open need for randomized validation before practice change.
Safety and tolerability of a one-step tilt table test with high dose (5 micrograms/min) isoproterenol (ISO) without intermediate stages were evaluated in a symptomatic population of 300 patients referred for clinical syncope, near syncope, or dizziness. ISO has been used as a provocative test but remains controversial. A population of 118 male and 182 female patients with a mean age of 45 (range 5-90) years underwent 300 tests. Heart rate and blood pressure were monitored continuously. A positive test was one in which clinical symptoms were reproduced or hemodynamic criteria met. Patients were initially supine for 5 minutes followed by head upright tilt (HUT) to an angle of 80 degrees for 10 minutes. Negative tests were repeated with an infusion of ISO at a rate of 5 micrograms/min. HUT was positive in 133 (44.3%) of 300 tests. With a 10-minute HUT alone, only 17 (5.7%) of 300 of tests were positive. Of the initial negative tests, 273 of 283 were tested with ISO. With ISO, 116 (42.5%) of 273 were positive. ISO in high dose (5 micrograms/min) was used in 264 of 273 patients, while low dose (1.0-2.5 micrograms/min) was used in 9 of 273 under special circumstances. High dose ISO was tolerated in 164 (62.1%) of 264 patients, reduced in 87 (33%) of 264, and discontinued in 11 (4.2%) of 264. Reasons for reduction included tachycardia (40 patients), nausea (31 patients), chest pain (2 patients), arrhythmia (5 patients), or other (9 patients). Adverse effects resolved within 1 minute of dose reduction. This one-step high dose ISO protocol reproduced neurocardiogenic syncope in symptomatic patients who tested negative without ISO and was safe, tolerated, and expeditious.
No takes yet. Share an insight, caveat, or question.
Vlay et al. (2000) conducted an observational in Suspected neurocardiogenic syncope, near syncope, or dizziness (n=300). High-dose isoproterenol (ISO) during tilt table test vs. Head upright tilt (HUT) alone was evaluated on Positive test (reproduction of clinical symptoms or hemodynamic criteria met). A one-step tilt table test with high-dose isoproterenol safely reproduced neurocardiogenic syncope in 42.5% of symptomatic patients who initially tested negative with head-up tilt alone (5.7%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: